OncoMatch/Clinical Trials/NCT04005690
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Is NCT04005690 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments for locally advanced pancreatic ductal adenocarcinoma.
Treatment: Cobimetinib · Olaparib · Onvansertib · Azenosertib · Saruparib · Tremelimumab — This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib, or olaparib, or onvansertib or azenosertib, or AZD5305, or tremelimumab will work better than standard treatments in patients with pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: wee1 inhibitor
Cannot have received: immunotherapy
Lab requirements
Blood counts
Hemoglobin >= 9.0 g/dL with no blood transfusion within 28 days; WBC > 3 x 10^9/L; ANC >= 1.5 x 10^9/L; Platelet count >= 100 x 10^9/L
Kidney function
Creatinine <= 1.5 x ULN, OR measured or calculated creatinine clearance >= 60 mL/min/1.73m^2 for participants with creatinine levels > 1.5 x institutional ULN
Liver function
Serum bilirubin <= 1.5 x institutional ULN; AST and ALT <= 2.5 x ULN
Cardiac function
12-lead ECG demonstrating QTcF <= 480 ms (AZENOSERTIB); QTcF <= 470 ms for females or <= 450 ms for males (general); No history or current evidence of congenital or family history of long QT syndrome or Torsade de Pointes; No clinically significant and/or uncontrolled heart disease such as congestive heart failure (NYHA >= 2), uncontrolled hypertension, or clinically significant arrhythmia currently requiring medical treatment; No acute myocardial infarction or unstable angina pectoris < 6 months prior to screening
Hemoglobin >= 9.0 g/dL with no blood transfusion within 28 days... WBC > 3 x 10^9/L... ANC >= 1.5 x 10^9/L... Platelet count >= 100 x 10^9/L... Creatinine <= 1.5 x ULN, OR measured or calculated creatinine clearance >= 60 mL/min/1.73m^2... Serum bilirubin <= 1.5 x institutional ULN... AST and ALT <= 2.5 x ULN... 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of >480 ms, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OHSU Knight Cancer Institute · Portland, Oregon
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify